AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10360414 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized interpersonal psychotherapy
Number of subjects: 160
Study 10360414 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy with nortriptyline
Number of subjects: 160
Study 7732992 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis with intravenous tissue plasminogen activator or urokinase
Number of subjects: 1229
Study 1742488 — intervention group
Group type: EXPERIMENTAL
Intervention: AP score < 130
Number of subjects: 399
Study 1742488 — intervention group
Group type: COMPARATOR
Intervention: AP score ≥ 130
Number of subjects: 399
Study 1742488 — intervention group
Group type: EXPERIMENTAL
Intervention: AP scores
Number of subjects: 399
Study 1742488 — intervention group
Group type: EXPERIMENTAL
Intervention: BG scores
Number of subjects: 399
Study 1742488 — intervention group
Group type: EXPERIMENTAL
Intervention: Low AP score
Number of subjects: 399
Study 1742488 — intervention group
Group type: EXPERIMENTAL
Intervention: BG
Number of subjects: 399
Study 6816626 — intervention group
Group type: EXPERIMENTAL
Intervention: Tube extension to terbutaline sulphate aerosol
Number of subjects: 23
Study 6816626 — intervention group
Group type: COMPARATOR
Intervention: Ordinary actuator
Number of subjects: 23
Study 30727982 — intervention group
Group type: EXPERIMENTAL
Intervention: Phaco‐viscocanalostomy with Ologen® implant (OloPhacovisco group)
Number of subjects: 79
Study 30727982 — intervention group
Group type: COMPARATOR
Intervention: Phaco‐viscocanalostomy (Phacovisco group)
Number of subjects: 79
Study 29398571 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegan eating plan
Number of subjects: 45
Study 29398571 — intervention group
Group type: COMPARATOR
Intervention: Portion-controlled eating plan
Number of subjects: 45
Study 26988845 — intervention group
Group type: EXPERIMENTAL
Intervention: L-based supplement
Number of subjects: 52
Study 26988845 — intervention group
Group type: COMPARATOR
Intervention: No supplement (non-treated group)
Number of subjects: 52
Study 25003921 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal electrical stimulation
Number of subjects: 48
Study 25003921 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal electrical stimulation plus pelvic floor muscle training
Number of subjects: 48
Study 21895920 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitiglinide (5-20 mg/meal)
Number of subjects: 225
Study 21895920 — intervention group
Group type: COMPARATOR
Intervention: Nateglinide (60-120 mg/meal)
Number of subjects: 225
Study 21895920 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitiglinide
Number of subjects: 225
Study 21895920 — intervention group
Group type: COMPARATOR
Intervention: Nateglinide
Number of subjects: 225
Study 21895920 — intervention group
Group type: COMPARATOR
Intervention: Mitiglinide and Nateglinide
Number of subjects: 225
Study 19292750 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient-fortified maize-soy flour (Likuni Phala, LP)
Number of subjects: 176
Study 19292750 — intervention group
Group type: EXPERIMENTAL
Intervention: Ready-to-use fortified spread (FS)
Number of subjects: 176
Study 17485918 — intervention group
Group type: EXPERIMENTAL
Intervention: Boron neutron capture therapy (BNCT)
Number of subjects: 35
Study 17485918 — intervention group
Group type: COMPARATOR
Intervention: Radioiodine treatment (3.3-5.6 GBq)
Number of subjects: 35
Study 15205198 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-Carboplatin (CRP-PCT) - CRP 6 AUC and PCT 175 mg/m² every 3 weeks for six cycles
Number of subjects: 360
Study 15205198 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-Vinorelbine (VRL-PCT) - VRL 25 mg/m² and PCT 135 mg/m² every 2 weeks for nine cycles
Number of subjects: 360
Study 11579369 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (up to 75 mg/d)
Number of subjects: 250
Study 11579369 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (up to 200 mg/d)
Number of subjects: 250
Study 11579369 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril and Metoprolol (both)
Number of subjects: 250
Study 11579369 — intervention group
Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 250
Study 11579369 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 250
Study 9540294 — intervention group
Group type: EXPERIMENTAL
Intervention: 32 h on-call shift
Number of subjects: 16
Study 7986470 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II infusion (2 ng/kg/min) with 3% saline infusion (0.1 mL/kg/min)
Number of subjects: 13
Study 7986470 — intervention group
Group type: COMPARATOR
Intervention: 3% saline infusion (0.1 mL/kg/min) alone
Number of subjects: 13
Study 7986470 — intervention group
Group type: COMPARATOR
Intervention: Phenylephrine infusion with 3% saline infusion (0.1 mL/kg/min)
Number of subjects: 13
Study 7986470 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II infusion (2 ng/kg/min) alone
Number of subjects: 13
Study 2645421 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxacin 400 mg orally every 12 hours for 14 days
Number of subjects: 249
Study 2645421 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim 160 mg plus Sulfamethoxazole 800 mg orally every 12 hours for 14 days
Number of subjects: 249
Study 2645421 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxacin 400 mg
Number of subjects: 249
Study 2645421 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim 160 mg plus Sulfamethoxazole 800 mg
Number of subjects: 249
Study 31992372 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed oil (20 g/d)
Number of subjects: 68
Study 31992372 — intervention group
Group type: COMPARATOR
Intervention: Sunflower oil (20 g/d)
Number of subjects: 68
Study 30630494 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxm Skate rehabilitation program
Number of subjects: 116
Study 30630494 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitative care
Number of subjects: 116
Study 29017565 — intervention group
Group type: EXPERIMENTAL
Intervention: Qishen granules (QSG)
Number of subjects: 200
Study 29017565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 25575488 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine 15 mg
Number of subjects: 614
Study 25575488 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine 20 mg
Number of subjects: 614
Study 25575488 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg (active reference)
Number of subjects: 614
Study 25575488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 614
Study 24469530 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise
Number of subjects: 202
Study 24469530 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise
Number of subjects: 202
Study 24469530 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline therapy
Number of subjects: 202
Study 24469530 — intervention group
Group type: COMPARATOR
Intervention: Placebo pill
Number of subjects: 202
Study 24469530 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual insomnia symptoms after treatment
Number of subjects: 202
Study 21842145 — intervention group
Group type: COMPARATOR
Intervention: Formocresol
Number of subjects: 107
Study 21842145 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser
Number of subjects: 107
Study 21842145 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide
Number of subjects: 107
Study 21842145 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric sulphate
Number of subjects: 107
Study 19577132 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous force of 225 cN for 8 weeks
Number of subjects: 8
Study 19577132 — intervention group
Group type: COMPARATOR
Intervention: Intermittent force of 225 cN for 8 weeks (14 days of force application, 3 days of rest, then 4 days of force application repeated for 6 weeks)
Number of subjects: 8
Study 17295689 — intervention group
Group type: EXPERIMENTAL
Intervention: HICC-containing deodorants (200, 600, and 1800 p.p.m.)
Number of subjects: 15
Study 17295689 — intervention group
Group type: EXPERIMENTAL
Intervention: HICC-containing deodorants (200 p.p.m.)
Number of subjects: 15
Study 17295689 — intervention group
Group type: EXPERIMENTAL
Intervention: Patch test thresholds of HICC solutions
Number of subjects: 15
Study 17295689 — intervention group
Group type: EXPERIMENTAL
Intervention: Patch test thresholds of HICC-scented deodorants
Number of subjects: 15
Study 16029507 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention program (increased intake of calcium-rich foods and weight-bearing physical activity)
Number of subjects: 30
Study 16029507 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 30
Study 12014291 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-session 24-hour cognitive-behavioral therapy program
Number of subjects: 0
Study 9440372 — intervention group
Group type: COMPARATOR
Intervention: 0 g fat meal
Number of subjects: 8
Study 9440372 — intervention group
Group type: COMPARATOR
Intervention: 15 g fat meal
Number of subjects: 8
Study 9440372 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g fat meal
Number of subjects: 8
Study 9440372 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 g fat meal
Number of subjects: 8
Study 9440372 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g fat meal
Number of subjects: 8
Study 8586298 — intervention group
Group type: COMPARATOR
Intervention: Intrauterine Insemination (IIU)
Number of subjects: 60
Study 8586298 — intervention group
Group type: EXPERIMENTAL
Intervention: Fallopian Tube Sperm Perfusion (PTE)
Number of subjects: 60
Study 2151278 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoladex depot alone, 3.6 mg subcutaneously every 28 days
Number of subjects: 328
Study 2151278 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoladex depot plus cyproterone acetate (CPA), 200 mg/day orally
Number of subjects: 328
Study 2151278 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoladex plus CPA
Number of subjects: 328
Study 2151278 — intervention group
Group type: COMPARATOR
Intervention: Zoladex depot alone
Number of subjects: 328
Study 345826 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenelzine (mean dose of 78 mg/day for 3 weeks)
Number of subjects: 19
Study 345826 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamilton Depression Rating Scale
Number of subjects: 19
Study 345826 — intervention group
Group type: EXPERIMENTAL
Intervention: Beck Depression Inventory
Number of subjects: 19
Study 345826 — intervention group
Group type: EXPERIMENTAL
Intervention: SCL‐90
Number of subjects: 19
Study 31704948 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 10 mg/day
Number of subjects: 550
Study 31704948 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg/day
Number of subjects: 550
Study 31704948 — intervention group
Group type: COMPARATOR
Intervention: Without Simvastatin (WS)
Number of subjects: 550
Study 31704948 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/day
Number of subjects: 550
Study 31704948 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg/day
Number of subjects: 550
Study 29026385 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine infusion (0.1mg/kg bolus followed by 2ug/kg/min infusion)
Number of subjects: 46
Study 29026385 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (physiological saline bolus followed by saline infusion)
Number of subjects: 46
Study 29026385 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 46
Study 29026385 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine infusion
Number of subjects: 46
Study 29026385 — intervention group
Group type: COMPARATOR
Intervention: Ketamine infusion and Saline infusion
Number of subjects: 46
Study 25940554 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/ml mitomycin-C (MMC) applied for 1 min
Number of subjects: 50
Study 25940554 — intervention group
Group type: COMPARATOR
Intervention: 0.2 mg/ml mitomycin-C (MMC) applied for 1 min
Number of subjects: 50
Study 23168285 — intervention group
Group type: EXPERIMENTAL
Intervention: Niacin
Number of subjects: 407
Study 23168285 — intervention group
Group type: COMPARATOR
Intervention: Control (no niacin)
Number of subjects: 407
Study 21307015 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic Focus (HF)
Number of subjects: 92
Study 21307015 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 92
Study 19852811 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily SMS reminders
Number of subjects: 424
Study 19852811 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SMS reminders)
Number of subjects: 424
Study 16333854 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA velocity > 0.0 ng/mL per month
Number of subjects: 213
Study 16333854 — intervention group
Group type: COMPARATOR
Intervention: PSA velocity <= 0.0 ng/mL per month
Number of subjects: 213
Study 15300656 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline 1 mg/day
Number of subjects: 56
Study 15300656 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline 2 mg/day
Number of subjects: 56
Study 15300656 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline 4 mg/day
Number of subjects: 56
Study 15300656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 15300656 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline (all doses combined)
Number of subjects: 56
Study 10408537 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta‐1a (IFN‐beta) 3 MIU for 2 weeks and then 6 MIU for 10 weeks, subcutaneously three times weekly
Number of subjects: 10
Study 10408537 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8786722 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately energy-restricted diet (80% of habitual intake)
Number of subjects: 24
Study 8786722 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 24
Study 2276384 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam 2 mg
Number of subjects: 0
Study 2276384 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (combined with Alprazolam)
Number of subjects: 0
Study 2276384 — intervention group
Group type: COMPARATOR
Intervention: Low dose alprazolam
Number of subjects: 0
Study 2276384 — intervention group
Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 0
Study 2276384 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7405924 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone retention enemas (Rectoid)
Number of subjects: 12
Study 7405924 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone retention enemas (Cortenema)
Number of subjects: 12
Study 7405924 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone retention enemas (Rectoid and Cortenema)
Number of subjects: 12
Study 30704764 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole (iron chelator plus pantoprazole)
Number of subjects: 60
Study 30704764 — intervention group
Group type: COMPARATOR
Intervention: Control (iron chelator)
Number of subjects: 60
Study 28498942 — intervention group
Group type: EXPERIMENTAL
Intervention: 4000 IU vitamin D daily
Number of subjects: 400
Study 28498942 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 24512248 — intervention group
Group type: EXPERIMENTAL
Intervention: Disgust induction
Number of subjects: 90
Study 24512248 — intervention group
Group type: EXPERIMENTAL
Intervention: Embarrassment induction
Number of subjects: 90
Study 24512248 — intervention group
Group type: COMPARATOR
Intervention: Control (no emotion)
Number of subjects: 90
Study 22805324 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA screening
Number of subjects: 0
Study 22805324 — intervention group
Group type: COMPARATOR
Intervention: No screening
Number of subjects: 0
Study 20230460 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention (8-week aerobic conditioning followed by 16-week maintenance)
Number of subjects: 0
Study 17620494 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine (intervention in a randomized, double-blind, placebo-controlled trial)
Number of subjects: 896
Study 17620494 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control in a randomized, double-blind, placebo-controlled trial)
Number of subjects: 896
Study 15567174 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined high-throughput analyses (HTA)
Number of subjects: 9
Study 15567174 — intervention group
Group type: EXPERIMENTAL
Intervention: Microarray analysis
Number of subjects: 9
Study 15567174 — intervention group
Group type: EXPERIMENTAL
Intervention: SAGE and EST analyses
Number of subjects: 9
Study 15567174 — intervention group
Group type: EXPERIMENTAL
Intervention: RT-PCR validation
Number of subjects: 9
Study 15567174 — intervention group
Group type: EXPERIMENTAL
Intervention: Human Breast Cancer Tissue Profiling Array
Number of subjects: 9
Study 15567174 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunohistochemical staining
Number of subjects: 9
Study 12000349 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral health care education programme (OHCE)
Number of subjects: 369
Study 12000349 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 369
Study 10446819 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor Activity Assessment Scale (MAAS)
Number of subjects: 25
Study 7615597 — intervention group
Group type: EXPERIMENTAL
Intervention: Ring polyethylene cementless cup
Number of subjects: 126
Study 2085969 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 600 mg single oral dose
Number of subjects: 40
Study 2085969 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 10246462 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education interventions
Number of subjects: 0
Study 10246462 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline questionnaire and group method for internality training
Number of subjects: 0
Study 31654645 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 60
Study 31654645 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen
Number of subjects: 60
Study 31100723 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational device (Maverick total disc replacement)
Number of subjects: 577
Study 31100723 — intervention group
Group type: COMPARATOR
Intervention: Control (anterior lumbar interbody fusion)
Number of subjects: 577
Study 28869722 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 25 mg lozenge
Number of subjects: 385
Study 28869722 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 385
Study 25728546 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl ITS at 170 μA
Number of subjects: 52
Study 25728546 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl ITS at 140 μA
Number of subjects: 52
Study 25728546 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl ITS at 200 μA
Number of subjects: 52
Study 25728546 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl ITS at 230 μA
Number of subjects: 52
Study 25728546 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fentanyl citrate
Number of subjects: 52
Study 25693333 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 0.5 mg kg‐1
Number of subjects: 99
Study 25693333 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 8.0 mg kg‐1
Number of subjects: 99
Study 25693333 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex
Number of subjects: 99
Study 21037268 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal levobupivacaine 6.2 mg (ED₅₀)
Number of subjects: 85
Study 21037268 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal levobupivacaine 12.9 mg (ED₉₅)
Number of subjects: 85
Study 21037268 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural anaesthesia with intrathecal morphine 100 µg and intrathecal sufentanil 2.5 µg
Number of subjects: 85
Study 21037268 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater doses of levobupivacaine
Number of subjects: 85
Study 19418823 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracycline-containing regimens
Number of subjects: 0
Study 19418823 — intervention group
Group type: COMPARATOR
Intervention: Non-anthracycline-containing regimens
Number of subjects: 0
Study 18261363 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg rosiglitazone
Number of subjects: 12
Study 18261363 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg rosiglitazone
Number of subjects: 12
Study 18261363 — intervention group
Group type: COMPARATOR
Intervention: Caucasian subjects (control group)
Number of subjects: 12
Study 18261363 — intervention group
Group type: EXPERIMENTAL
Intervention: Japanese subjects
Number of subjects: 12
Study 18261363 — intervention group
Group type: EXPERIMENTAL
Intervention: Korean subjects
Number of subjects: 12
Study 18261363 — intervention group
Group type: EXPERIMENTAL
Intervention: Mainland Chinese subjects
Number of subjects: 12
Study 16887854 — intervention group
Group type: EXPERIMENTAL
Intervention: Achievement of NCEP LDL-C goal <1.8 mmol/L
Number of subjects: 634
Study 16887854 — intervention group
Group type: COMPARATOR
Intervention: Statin regimen intensity
Number of subjects: 634
Study 15362593 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal (50 g) with atropine (0.01 mg/kg I.M. administered 15 min prior to acetaminophen ingestion)
Number of subjects: 10
Study 15362593 — intervention group
Group type: COMPARATOR
Intervention: Activated charcoal (50 g) alone
Number of subjects: 10
Study 15362593 — intervention group
Group type: COMPARATOR
Intervention: Control (no activated charcoal or atropine)
Number of subjects: 10
Study 11115081 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-hirudin (PEG-Hi) 0.05 mg/kg body weight, single intravenous bolus injection
Number of subjects: 38
Study 11115081 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-hirudin (PEG-Hi)
Number of subjects: 38
Study 8861828 — intervention group
Group type: EXPERIMENTAL
Intervention: Solution of 60 mg/ml paracetamol, 1000 mg dose
Number of subjects: 10
Study 8861828 — intervention group
Group type: COMPARATOR
Intervention: Fatty suppository, 1000 mg dose
Number of subjects: 10
Study 1798005 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytime ambulatory blood pressure measurement
Number of subjects: 318